{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:31:42Z","timestamp":1786555902615,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.therap.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T02:36:18Z","timestamp":1758508578000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Isolated depressive disorders and suicidality with finasteride use for androgenetic alopecia: A call for enhanced vigilance"],"prefix":"10.1016","volume":"81","author":[{"given":"H\u00e9l\u00e8ne","family":"G\u00e9niaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-0359","authenticated-orcid":false,"given":"Marie-Laure","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.09.004_bib0205","first-page":"703","article-title":"The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness","volume":"79","author":"Dallob","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2025.09.004_bib0210","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0190-9622(99)70081-2","article-title":"Finasteride in the treatment of men with frontal male pattern hair loss","volume":"40","author":"Leyden","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2025.09.004_bib0215","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/archdermatol.2010.256","article-title":"Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review","volume":"146","author":"Mella","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2025.09.004_bib0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","article-title":"Finasteride in the treatment of men with androgenetic alopecia","volume":"39","author":"Kaufman","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2025.09.004_bib0225","first-page":"e42768","article-title":"Comparing current therapeutic modalities of androgenic alopecia: a literature review of clinical trials","volume":"15","author":"Bajoria","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.therap.2025.09.004_bib0230","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/phar.1837","article-title":"Persistent sexual dysfunction with finasteride 1mg taken for hair loss","volume":"36","author":"Guo","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2025.09.004_bib0235","series-title":"Finasteride- and dutasteride-containing medicinal products - referral","year":"2025"},{"key":"10.1016\/j.therap.2025.09.004_bib0395","series-title":"Archives ANSM","year":"2017"},{"key":"10.1016\/j.therap.2025.09.004_bib0400","series-title":"ANSM","year":"2020"},{"key":"10.1016\/j.therap.2025.09.004_bib0240","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.euf.2024.04.009","article-title":"Association of 5\u03b1-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis","volume":"10","author":"Uleri","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.therap.2025.09.004_bib0245","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","article-title":"Association of suicidality and depression with 5\u03b1-reductase inhibitors","volume":"177","author":"Welk","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.therap.2025.09.004_bib0250","doi-asserted-by":"crossref","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","article-title":"Association of 5\u03b1-reductase inhibitors with dementia, depression, and suicide","volume":"5","author":"Garcia-Argibay","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2025.09.004_bib0255","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1038\/s41598-023-32356-3","article-title":"Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study","volume":"13","author":"Laanani","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2025.09.004_bib0260","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JU.0000000000001079","article-title":"Lack of association between 5\u03b1-reductase inhibitors and depression","volume":"204","author":"Dyson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.therap.2025.09.004_bib0265","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/phar.1925","article-title":"Risk of incident antidepressant-treated depression associated with use of 5\u03b1-reductase inhibitors compared with use of \u03b1-blockers in men with benign prostatic hyperplasia: a population-based study using the clinical practice research datalink","volume":"37","author":"Hagberg","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2025.09.004_bib0270","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/ajd.14359","article-title":"The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: a population-based case\u2013control study","volume":"65","author":"Lyakhovitsky","year":"2024","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.therap.2025.09.004_bib0275","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1346-8138.2002.tb00200.x","article-title":"Depression circumstantially related to the administration of finasteride for androgenetic alopecia","volume":"29","author":"Altomare","year":"2002","journal-title":"J Dermatol"},{"key":"10.1016\/j.therap.2025.09.004_bib0280","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2025.09.004_bib0285","first-page":"51","article-title":"Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?","volume":"7","author":"Singh","year":"2014","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.therap.2025.09.004_bib0290","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4111\/kju.2014.55.6.367","article-title":"The dark side of 5\u03b1-reductase inhibitors\u2019 therapy: sexual dysfunction, high Gleason grade prostate cancer and depression","volume":"55","author":"Traish","year":"2014","journal-title":"Korean J Urol"},{"key":"10.1016\/j.therap.2025.09.004_bib0295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-6-7","article-title":"Finasteride induced depression: a prospective study","volume":"6","author":"Rahimi-Ardabili","year":"2006","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.09.004_bib0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/7854_2020_165","article-title":"Sex, gender, and suicidal behavior","volume":"46","author":"Barrigon","year":"2020","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.therap.2025.09.004_bib0305","doi-asserted-by":"crossref","first-page":"e0129062","DOI":"10.1371\/journal.pone.0129062","article-title":"What are reasons for the large gender differences in the lethality of suicidal acts? An epidemiological analysis in four european countries","volume":"10","author":"Mergl","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.therap.2025.09.004_bib0310","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1111\/j.1743-6109.2012.02846.x","article-title":"Persistent sexual side effects of finasteride: could they be permanent?","volume":"9","author":"Irwig","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.therap.2025.09.004_bib0315","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/andr.12147","article-title":"An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia","volume":"4","author":"Chiriac\u00f2","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.therap.2025.09.004_bib0320","doi-asserted-by":"crossref","first-page":"e0309849","DOI":"10.1371\/journal.pone.0309849","article-title":"Multidimensional assessment of adverse events of finasteride: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024","volume":"20","author":"Zhong","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.therap.2025.09.004_bib0325","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JCP.0000000000001379","article-title":"Risk of depression associated with finasteride treatment","volume":"41","author":"Pompili","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2025.09.004_bib0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-002-1257-1","article-title":"Neurosteroids in depression: a review","volume":"165","author":"Van Broekhoven","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.therap.2025.09.004_bib0335","doi-asserted-by":"crossref","first-page":"101114","DOI":"10.1016\/j.yfrne.2023.101114","article-title":"Post-finasteride syndrome and post-ssri sexual dysfunction: two clinical conditions apparently distant, but very close","volume":"72","author":"Giatti","year":"2024","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.therap.2025.09.004_bib0340","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/HMBCI.2010.010","article-title":"The influence of low dose finasteride, a type II 5\u03b1-reductase inhibitor, on circulating neuroactive steroids","volume":"1","author":"Du\u0161kov\u00e1","year":"2010","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.therap.2025.09.004_bib0345","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1046\/j.1365-2133.1999.03030.x","article-title":"The psychosocial consequences of androgenetic alopecia: a review of the research literature: psychosocial consequences of androgenetic alopecia","volume":"141","author":"Cash","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2025.09.004_bib0350","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-3083.2001.00229.x","article-title":"The effect of hair loss on quality of life","volume":"15","author":"Williamson","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2025.09.004_bib0355","doi-asserted-by":"crossref","first-page":"82074","DOI":"10.18632\/oncotarget.12617","article-title":"Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.therap.2025.09.004_bib0360","series-title":"Base de donn\u00e9es publique des m\u00e9dicaments","year":"2022"},{"key":"10.1016\/j.therap.2025.09.004_bib0365","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jdv.14624","article-title":"Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men\u2013short version","volume":"32","author":"Kanti","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2025.09.004_bib0370","first-page":"379","article-title":"Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study","volume":"18","author":"Lin","year":"2002","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.therap.2025.09.004_bib0375","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00345-020-03314-9","article-title":"An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors","volume":"39","author":"Harrell","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.therap.2025.09.004_bib0380","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.therap.2023.03.005","article-title":"Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran)","volume":"78","author":"Valnet-Rabier","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.09.004_bib0385","series-title":"Retinoid-containing medicinal products - referral","year":"2018"},{"key":"10.1016\/j.therap.2025.09.004_bib0390","series-title":"\u00c9pisode d\u00e9pressif caract\u00e9ris\u00e9 de l\u2019adulte\u00a0: prise en charge en soins de premier recours. Diagnostic","year":"2017"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:36:48Z","timestamp":1786552608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0040595725001106"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.09.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolated depressive disorders and suicidality with finasteride use for androgenetic alopecia: A call for enhanced vigilance","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}